BMEZ · NYSE · Closed-end fund
BlackRock Health Sciences Term Trust (BMEZ) Price, Holdings & Fees
BlackRock Health Sciences Term Trust (BMEZ) closed at $521.96 on Oct 9, 2026, up 0.58% from the previous close of $518.97.
Share price, past year
1Y +31.97%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $521.96 |
| Sep 30, 2026 | $505.33 |
| Aug 31, 2026 | $484.47 |
| Jul 31, 2026 | $450.28 |
| Jun 30, 2026 | $492.27 |
| May 29, 2026 | $487.91 |
| Apr 30, 2026 | $472.73 |
| Mar 31, 2026 | $454.12 |
| Feb 27, 2026 | $471.12 |
| Jan 30, 2026 | $446.17 |
| Dec 31, 2025 | $449.07 |
| Nov 28, 2025 | $416.93 |
| Oct 31, 2025 | $417.59 |
Key statistics
- Expense ratio
- —
- Net assets
- $1.1B
- as of Jun 30, 2026
- Holdings
- 175
- as of Jun 30, 2026
- 52-week range
- $395.50 – $522.72
Holdings
BlackRock Health Sciences Term Trust held 175 investments worth $1.08B as of Jun 30, 2026. Its largest holding was Moderna Inc, at 3.57% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Moderna Inc | 3.57% | $38.50M |
| 2 | Johnson & Johnson | 3.43% | $36.99M |
| 3 | Merck & Co Inc | 3.01% | $32.45M |
| 4 | Biogen Inc | 2.76% | $29.71M |
| 5 | PsiQuantum Corp | 2.56% | $27.62M |
| 6 | Gilead Sciences Inc | 2.52% | $27.13M |
| 7 | Edwards Lifesciences Corp | 2.33% | $25.14M |
| 8 | Neurocrine Biosciences Inc | 1.99% | $21.49M |
| 9 | Novartis AG | 1.98% | $21.38M |
| 10 | Amgen Inc | 1.92% | $20.70M |
| 11 | Illumina Inc | 1.90% | $20.46M |
| 12 | Roche Holding AG | 1.77% | $19.09M |
| 13 | Thermo Fisher Scientific Inc | 1.62% | $17.45M |
| 14 | AbbVie Inc | 1.59% | $17.10M |
| 15 | Genmab A/S | 1.48% | $15.94M |
| 16 | Axsome Therapeutics Inc | 1.43% | $15.40M |
| 17 | Danaher Corp | 1.40% | $15.11M |
| 18 | Agilent Technologies Inc | 1.39% | $14.95M |
| 19 | Natera Inc | 1.31% | $14.15M |
| 20 | BlackRock Liquidity Funds | 1.30% | $13.96M |
| 21 | Cytokinetics Inc | 1.29% | $13.85M |
| 22 | Charles River Laboratories International Inc | 1.28% | $13.81M |
| 23 | UnitedHealth Group Inc | 1.27% | $13.70M |
| 24 | GSK PLC | 1.27% | $13.70M |
| 25 | Guardant Health Inc | 1.25% | $13.47M |
Top 25 of 175 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 95.76% |
| Cash and short-term investments | 2.88% |
| Preferred stock | 1.68% |
| Other | 0.03% |
| Country | % of fund |
|---|---|
| United States | 79.38% |
| Switzerland | 6.29% |
| United Kingdom | 4.75% |
| Denmark | 1.67% |
| Belgium | 1.25% |
| Germany | 1.25% |
| Netherlands | 1.03% |
| Japan | 0.85% |
| Ireland | 0.81% |
| Bermuda | 0.79% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jun 30, 2026, BlackRock Health Sciences Term Trust's total return was +8.82%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jun 30, 2026 | +7.71% |
| May 31, 2026 | +2.66% |
| Apr 30, 2026 | −1.59% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- BlackRock Health Sciences Term Trust
- Ticker
- BMEZ
- Exchange
- NYSE
- Fund type
- Closed-end fund
- SEC CIK
- 0001785971
- Fractional shares
- Yes
Recent SEC filings
- Aug 25, 2026
- Sep 3, 2026
- Mar 5, 2026
- Sep 4, 2025
- Mar 7, 2025
- Sep 5, 2024
- Mar 6, 2024
- Sep 1, 2023
Frequently asked questions
What is BMEZ's price?
BlackRock Health Sciences Term Trust (BMEZ) closed at $521.96 on Oct 9, 2026, up 0.58% from the previous close of $518.97.
What does BMEZ hold?
BlackRock Health Sciences Term Trust held 175 investments worth $1.08B as of Jun 30, 2026. Its largest holding was Moderna Inc, at 3.57% of the fund. Its five largest holdings were Moderna Inc, Johnson & Johnson, Merck & Co Inc, Biogen Inc, PsiQuantum Corp.
How has BMEZ performed?
Over the 3 months to Jun 30, 2026, BlackRock Health Sciences Term Trust's total return was +8.82%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 25, 2026). Prices are generated sample data for development. Data sources and disclosures